Marker Therapeutics (NASDAQ:MRKR) Price Target Raised to $19.00

Marker Therapeutics (NASDAQ:MRKR) had its target price upped by LADENBURG THALM/SH SH from $11.00 to $19.00 in a research report report published on Monday morning, Benzinga reports. They currently have a buy rating on the stock.

Marker Therapeutics Stock Down 11.1 %

NASDAQ:MRKR opened at $4.01 on Monday. Marker Therapeutics has a 12 month low of $2.40 and a 12 month high of $6.16. The firm’s 50 day moving average is $3.15 and its 200 day moving average is $3.98.

Marker Therapeutics (NASDAQ:MRKR) last issued its earnings results on Wednesday, August 14th. The company reported ($0.25) earnings per share (EPS) for the quarter. The firm had revenue of $1.17 million during the quarter. Marker Therapeutics had a negative net margin of 278.27% and a negative return on equity of 78.91%. As a group, equities research analysts anticipate that Marker Therapeutics will post -1.43 earnings per share for the current year.

Hedge Funds Weigh In On Marker Therapeutics

An institutional investor recently raised its position in Marker Therapeutics stock. Wedbush Securities Inc. boosted its holdings in Marker Therapeutics, Inc. (NASDAQ:MRKR) by 52.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 69,500 shares of the company’s stock after buying an additional 24,000 shares during the period. Wedbush Securities Inc. owned approximately 0.78% of Marker Therapeutics worth $377,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 22.39% of the company’s stock.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.